Skip to main content
. 2023 Sep 13;46(10):1365–1374. doi: 10.1007/s00270-023-03545-4

Table 3.

Follow-up

Follow-up
Median follow-up (months, range) 16 5–22
Follow-up modality
 MRI only 11 57%
 MRI + CT 7 37%
 MRI + 18FFDG-PET 1 5%
Patients with tumor recurrence (concerning the ablated tumor) 0 0%
Patients with new liver tumors (other than ablated tumors) 6 32%
Patients with progressive or new tumors outside the liver 3 16%
Complications
 Complicated procedures 2 10%
 Uncomplicated procedures 17 90%
 Grade 2 1 5%
 Grade 3 1 5%